# Ultradian Subcutaneous Hydrocortisone Infusion in Addison Disease and Congenital Adrenal Hyperplasia

> **NCT02096510** · PHASE1,PHASE2 · COMPLETED · sponsor: **Haukeland University Hospital** · enrollment: 8 (actual)

## Conditions studied

- Addison Disease
- Adrenal Hyperplasia Congenital

## Interventions

- **DRUG:** Solu-Cortef
- **DRUG:** Cortef

## Key facts

- **NCT ID:** NCT02096510
- **Lead sponsor:** Haukeland University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03-27
- **Primary completion:** 2016-12
- **Final completion:** 2017-12
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2024-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02096510

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02096510, "Ultradian Subcutaneous Hydrocortisone Infusion in Addison Disease and Congenital Adrenal Hyperplasia". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02096510. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*